Dorigatti et al., 2021 - Google Patents
SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo'Dorigatti et al., 2021
View HTML- Document ID
- 15281809649331451854
- Author
- Dorigatti I
- Lavezzo E
- Manuto L
- Ciavarella C
- Pacenti M
- Boldrin C
- Cattai M
- Saluzzo F
- Franchin E
- Del Vecchio C
- Caldart F
- Castelli G
- Nicoletti M
- Nieddu E
- Salvadoretti E
- Labella B
- Fava L
- Guglielmo S
- Fascina M
- Grazioli M
- Alvisi G
- Vanuzzo M
- Zupo T
- Calandrin R
- Lisi V
- Rossi L
- Castagliuolo I
- Merigliano S
- Unwin H
- Plebani M
- Padoan A
- Brazzale A
- Toppo S
- Ferguson N
- Donnelly C
- Crisanti A
- Publication year
- Publication venue
- Nature Communications
External Links
Snippet
Abstract In February and March 2020, two mass swab testing campaigns were conducted in Vo', Italy. In May 2020, we tested 86% of the Vo'population with three immuno-assays detecting antibodies against the spike and nucleocapsid antigens, a neutralisation assay …
- 108090001123 antibodies 0 title abstract description 63
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/576—Immunoassay; Biospecific binding assay for hepatitis
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F21/00—Security arrangements for protecting computers, components thereof, programs or data against unauthorised activity
- G06F21/50—Monitoring users, programs or devices to maintain the integrity of platforms, e.g. of processors, firmware or operating systems
- G06F21/55—Detecting local intrusion or implementing counter-measures
- G06F21/56—Computer malware detection or handling, e.g. anti-virus arrangements
- G06F21/562—Static detection
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
- G06F17/30—Information retrieval; Database structures therefor; File system structures therefor
- G06F17/30286—Information retrieval; Database structures therefor; File system structures therefor in structured data stores
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/36—Computer-assisted acquisition of medical data, e.g. computerised clinical trials or questionnaires
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
- G06F17/20—Handling natural language data
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dorigatti et al. | SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo’ | |
| Ortega et al. | Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses | |
| Pritchard et al. | Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom | |
| Goldberg et al. | Swift and extensive Omicron outbreak in China after sudden exit from ‘zero-COVID’policy | |
| Manisty et al. | Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infection | |
| Accorsi et al. | How to detect and reduce potential sources of biases in studies of SARS-CoV-2 and COVID-19 | |
| den Hartog et al. | SARS-CoV-2–specific antibody detection for seroepidemiology: a multiplex analysis approach accounting for accurate seroprevalence | |
| Zhang et al. | Insight into the practical performance of RT-PCR testing for SARS-CoV-2 using serological data: a cohort study | |
| Bonfante et al. | Mild SARS-CoV-2 infections and neutralizing antibody titers | |
| Aguas et al. | Cross-serotype interactions and disease outcome prediction of dengue infections in Vietnam | |
| Aldridge et al. | SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort | |
| Karachaliou et al. | Infection induced SARS-CoV-2 seroprevalence and heterogeneity of antibody responses in a general population cohort study in Catalonia Spain | |
| Van Kerkhove et al. | Studies needed to address public health challenges of the 2009 H1N1 influenza pandemic: insights from modeling | |
| Fisman et al. | COVID-19 case age distribution: correction for differential testing by age | |
| Shrotri et al. | Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study | |
| de Gier et al. | Effects of COVID-19 vaccination and previous infection on Omicron SARS-CoV-2 infection and relation with serology | |
| Sun et al. | Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa | |
| Garriga et al. | Mortality, causes of death and associated factors relate to a large HIV population-based cohort | |
| Kaufman et al. | Insights from patterns of SARS-CoV-2 immunoglobulin G serology test results from a national clinical laboratory, United States, March–July 2020 | |
| Eyre et al. | Stringent thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections | |
| Xie et al. | Resurgence of omicron BA. 2 in SARS-CoV-2 infection-naive Hong Kong | |
| Movsisyan et al. | Kinetics of anti-nucleocapsid IgG response in COVID-19 immunocompetent convalescent patients | |
| Perez-Saez et al. | Long term anti-SARS-CoV-2 antibody kinetics and correlate of protection against Omicron BA. 1/BA. 2 infection | |
| Wang et al. | Long-term measles antibody profiles following different vaccine schedules in China, a longitudinal study | |
| Michaelis et al. | Hepatitis A virus infections, immunisations and demographic determinants in children and adolescents, Germany |